Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ID93 + GLA-SE therapeutic vaccination in rifampicin-susceptible pulmonary tuberculosis
PACTR202509920781530Phase 2Not yet recruiting
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Aug 2025
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of ID93 and GLA-SE adjuvant in pulmonary tuberculosis (TB), sponsored by National Institute of Allergy and Infectious Diseases. Primary endpoint: Safety of two-dose ID93 + GLA-SE regimen. Planned start Aug 2025; status: not yet recruiting.
02
Drugs
ID93GLA-SE adjuvant
03
Conditions
pulmonary tuberculosis (TB)
Beyond the preview
Go deeper on PACTR202509920781530.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR202509920781530.